Evorpacept is under clinical development by ALX Oncology Holdings and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Evorpacept’s likelihood of approval (LoA) and phase transition for Head And Neck Cancer Squamous Cell Carcinoma took place on 27 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 27 Dec 2022 increased Evorpacept’s LoA and PTSR for Recurrent Head And Neck Cancer Squamous Cell Carcinoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Evorpacept Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Evorpacept overview

evorpacept is under development for the treatment of advanced solid tumors including colorectal cancer, indolent and aggressive B-cell non-Hodgkin lymphoma, gastro-esophageal junction cancers, acute myeloid leukemia, relapsed/refractory acute myeloid leukemia, epithelial ovarian, endometrial cancer, urothelial cancers, recurrent head and neck cancer squamous cell carcinoma and relapsed or refractory, higher risk myelodysplastic syndrome, non-Hodgkin lymphoma including mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, metastatic gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma, metastatic transitional (urothelial) tract cancer. It is administered intravenously. The drug candidate is a fusion protein containing high affinity CD47 binding domain of SIRPalpha linked to an inactive Fc region of human immunoglobulin.

It was also under development for breast cancer, leiomyosarcoma, non-small cell lung cancer, pancreatic, peritoneal, appendiceal, thymic cancers.

ALX Oncology Holdings overview

ALX Oncology Holdings (ALXO) is an immune-oncology company that discovers and develops treatments for cancer and hematology indications. It is investigating its lead product candidate evorpacept (ALX148), a CD47 blocker for the treatment of hematologic and solid tumors; and ALTA-002, a SIRPa toll-like receptor agonist antibody conjugate (TRAAC) targeting advanced cancer. The company is also evaluating its lead candidate in combination with other agents against head and neck squamous cell carcinoma, gastric, urothelial, and breast cancer, myelodysplastic syndromes, acute myeloid leukemia, and non-Hodgkin’s lymphoma. ALXO is headquartered in South San Francisco, California, the US.

Quick View Evorpacept LOA Data

Report Segments
  • Innovator
Drug Name
  • Evorpacept
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: ALX Oncology Holdings
  • Originator: Stanford University
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.